- Company
- Ildong starts distribution of GSK generic drugs
- by Jung, Hye-Jin Jan 7, 2020 06:28am
- From the 6th, Ildong will begin supplying nine OTC drugs from GlaxoSmithKline. Orders from wholesalers and direct-selling pharmacies began on the 3rd, and the products are shipped from the 6th, depending on the order amount Under the co-promotion agreement with GSK, Ildong has sold a comprehensive cold medicine 'Theraflu', an ophthalmic
- Policy
- Derazantinib-Tecentriq trial approved in Korea
- by Lee, Jeong-Hwan Jan 7, 2020 06:28am
- A global clinical trial to test a combination therapy of anticancer treatment derazantinib and immunotherapy Tecentriq (atezolizumab) was approved in Korea to treat patients with urothelial cancer. The clinical trial has been put together as derazantinib developer Basilea Pharmaceutica and Tecentriq developer Roche have signed a collabor
- Policy
- Eliquis' price cut has been reserved
- by Kim, Jung-Ju Jan 6, 2020 11:00pm
- Against the government's lower policy price cut, the former drug price of BMS Eliquis (Apixaban), which is appealing to the court, will be temporarily held. Currently in progress at the Seoul High Court, if it is terminated, additional price cuts are scheduled for June 1st. The Seoul High Court's 9th Executive (2019-Ah1617) decided to t
- Company
- 5-year ‘Botox War’ to end this year
- by Kim, Jin-Gu Jan 6, 2020 11:00pm
- The legal dispute between Daewoong Pharmaceutical and Medytox over botulinum toxin strain would come to an end this year. While the industry predicts the final decision would be made in coming June, legal experts see either one of them losing the case would take a heavy blow. According to industry sources on Jan. 3, the U.S. Internat
- Policy
- Industry speculating on special clause for IMD
- by Lee, Jeong-Hwan Jan 6, 2020 06:22am
- While the government’s announcement on the revised drug pricing regulation has been delayed, the pharmaceutical industry is seemingly speculating on a possible new special clause of the regulation to exempt incrementally modified drug (IMD) with recognized non-obviousness. The industry predicts the government is more likely to make an exce
- Product
- Taltz for interleukin Psoriasis expands Rx Area in hospitals
- by Eo, Yun-Ho Jan 6, 2020 06:22am
- Lilly's interleukin IL-17A antagonist, Taltz, is settling on its prescription area at general hospitals. According to the related industry on the 6th, psoriasis treatment Taltz (Ixekizumab) passed the drug commitee (DC) of Seoul National Hospital recently after Asan Hospital and Severance Hospital among the Big Five. In addition, prescri
- Company
- BMS re-applied for suspension about Eliquis
- by Kim, Jin-Gu Jan 6, 2020 06:21am
- Eliquis' price has dropped by 30% since last 1st. This is in accordance with the Seoul Administrative Court's decision at the end of last year. However, It is also likely that drug prices will rise again in the 2nd course of legal disputes. The Ministry of Health and Welfare recently announced that Eliquis' suspension of price cuts has bee
- Policy
- Early market entry of Gabsmet salt-modifying drugs are noted
- by Lee, Tak-Sun Jan 6, 2020 06:21am
- The salt-modifying drug 'Galvusmet', a DPP-4 inhibitory diabetes drug, applied for approval for the first time in Korea on the 24th of last month. It is therefore noteworthy whether it will be released to the market early. According to the MFDS on the 24th, Vildagliptin HCl-Metformin HCl combination was applied for the first time to the pa
- Company
- SK gets world’s first quadrivalent flu vaccine PQ by WHO
- by Lee, Seok-Jun Jan 6, 2020 06:20am
- For the first time in the world, a quadrivalent influenza vaccine passed prequalification (PQ) by the World Health Organization (WHO). SK Bioscience announced on Jan. 2 WHO has completed the seven-month long PQ evaluation and granted a certification of PQ on its Sky Cellflu Quadrivalent. This marks the first time in the world history
- Company
- Nexavar reimbursement cleared for severe HCC patients
- by Eo, Yun-Ho Jan 6, 2020 06:20am
- From this year, reimbursed prescription would be granted on liver cancer treatment Nexavar treating patient with severe liver dysfunction. According to the new pharmaceutical listing, reimbursement on Nexavar (sorafenib) would be provided for a patient, including pediatric patient, with advanced hepatocelluar carcinoma (HCC) who is unabl
